Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label study of BBM-D101 for Duchenne muscular dystrophy
CTR20252461Phase 2Active
- Sponsor
- Xinzong Pharmaceutical Technology
- Start
- Jul 2025
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of BBM-D101 in Duchenne muscular dystrophy (DMD), sponsored by Xinzong Pharmaceutical Technology. Started Jul 2025; status: active.
02
Drugs
BBM-D101
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on CTR20252461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252461.